Skip to Content

Lexiscan Approval History

FDA Approved: Yes (First approved April 10, 2008)
Brand name: Lexiscan
Generic name: regadenoson
Dosage form: Injection
Company: CV Therapeutics, Inc.
Treatment for: Diagnosis and Investigation

Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

Development History and FDA Approval Process for Lexiscan

DateArticle
Apr 11, 2008Approval CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(regadenoson) Injection

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide